NOVEL SOLID FORMS (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID Russian patent published in 2024 - IPC C07D405/12 C07D455/06 A61K31/473 A61P25/00 C07H15/26 C07H17/02 A61K31/706 A61P25/16 A61P25/28 

FIELD: physics.

SUBSTANCE: invention relates to a solid form of a compound of formula (Id), where said solid form is selected from a group consisting of a dihydrate characterized by an X-ray powder diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 10.4, 11.6, 12.3, and 13.1, and 13.6°; anhydrate, characterized by a powder X-ray diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 8.5, 11.1, 12.4, 12.9 and 15.6°; heptahydrate, characterized by a powder X-ray diffraction pattern obtained using radiation CuKα1 (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 7.0, 8.6, 10.2, 11.1 and 11.9°; form A, characterized by a powder X-ray diffraction pattern obtained using radiation CuKα1 (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 7.6, 9.5, 10.0, 11.2 and 12.0°; form B, characterized by a powder X-ray diffraction pattern obtained using radiation CuKα1 (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 7.6, 9.0, 10.9, 12.3 and 14.3°; form C, characterized by a powder X-ray diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 7.5, 8.1, 10.3, 12.6 and 13.5°; monohydrate, characterized by X-ray powder diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 9.2, 10.2, 11.8, 12.6 and 13.6°; potassium salt, characterized by a powder X-ray diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 3.0, 9.0, 12.6, 13.6 and 15.0°; form of sodium salt 1, characterized by a powder X-ray diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 5.9, 8.9, 11.9, 12.8 and 13.8°; form of sodium salt 2, characterized by a powder X-ray diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 5.6, 8.5, 12.6, 13.6 and 14.1°; hydrochloride salt characterized by X-ray powder diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 5.7, 7.3, 10.6, 13.3 and 15.3°; and hydrobromide salt, characterized by X-ray powder diffraction pattern obtained using CuKα1 radiation (λ=1.5406 Å), containing peaks at the following angle values 2θ ± 0.2° 2θ: 12.5, 13.9, 14.5, 15.6 and 18.6°. Invention relates to a pharmaceutical composition for treating a neurodegenerative disease or a disorder containing a therapeutically effective amount of a solid form of a compound of formula (Id) according to the invention and one or more pharmaceutically acceptable excipients.

EFFECT: solid form of connection form of connection (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid of formula (Id) is intended for use in treating a neurodegenerative disease or disorder selected from Parkinson's disease, Huntington's disease, restless legs syndrome and Alzheimer's disease.

34 cl, 8 tbl, 21 dwg, 10 ex